Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar, George N. Thalmann et al.|The Lancet|2015Cited by 2k
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal CancerThomas Powles, Christy Ralph, Matthew Wheater et al.|European Urology|2015Cited by 100
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)Simon J. Crabb, Robert J. Jones, Gareth Griffiths et al.|Journal of Clinical Oncology|2020Cited by 82
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth Woods, Mark Sculpher, E.G. Sideris et al.|European Urology Oncology|2018Cited by 27
A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).Thomas Powles, Christy Ralph, Matthew Wheater et al.|Journal of Clinical Oncology|2015Cited by 5